{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:56:04Z","timestamp":1791593764980,"version":"4.3.4"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Older adults with lower intake and tissue levels of long-chain \u03c9-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA; 20:5) and docosahexaenoic acid (DHA; 22:6) have more brain white matter lesions (WMLs), an association suggesting that small-vessel ischemic disease, a major contributor to the development of dementia, including Alzheimer disease, may be preventable through \u03c9-3 treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether \u03c9-3 treatment reduces WML accumulation in older adults without dementia harboring WMLs and with suboptimal \u03c9-3 status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This quadruple-blinded, placebo-controlled, randomized clinical trial with treatment stratification by apolipoprotein E \u03b54 allele (<jats:italic>APOE*E4<\/jats:italic>) carrier status used linear mixed-effects models to estimate mean annual change between groups. The study was conducted at Oregon Health &amp;amp;amp; Science University, a major academic medical center in the Pacific Northwest, from May 2014 to final participant visit in September 2019. Data analysis concluded in July 2022. Participants were adults without dementia aged 75 years and older with WMLs greater than or equal to 5 cm<jats:sup>3<\/jats:sup> and plasma \u03c9-3 PUFA less than 5.5 weight percentage of total.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Three-year treatment with 1.65 g of \u03c9-3 PUFA (975 mg of EPA and 650 mg of DHA) vs a soybean oil placebo matched for taste, smell, and appearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was annual WML progression measured using magnetic resonance imaging. Secondary outcomes included diffusion tensor imaging of fractional anisotropy (DTI-FA), representing neuronal integrity breakdown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 102 participants (62 women [60.8%]; mean age, 81 years [range, 75-96 years]) were equally randomized, 51 per treatment group. Although the \u03c9-3 group had less annual WML accumulation than the placebo group, the difference was not statistically significant (1.19 cm<jats:sup>3<\/jats:sup> [95% CI, 0.64-1.74 cm<jats:sup>3<\/jats:sup>] vs 1.34 cm<jats:sup>3<\/jats:sup> [95% CI, 0.80-1.88 cm<jats:sup>3<\/jats:sup>]; <jats:italic>P<\/jats:italic>\u2009=\u2009.30). Similarly, the \u03c9-3 group had less annual DTI-FA decline than the placebo group, but the difference was not statistically significant (\u22120.0014 mm<jats:sup>2<\/jats:sup>\/s [95% CI, \u22120.0027 to 0.0002 mm<jats:sup>2<\/jats:sup>\/s] vs \u22120.0027 mm<jats:sup>2<\/jats:sup>\/s [95% CI, \u22120.0041 to \u22120.0014 mm<jats:sup>2<\/jats:sup>\/s]; <jats:italic>P<\/jats:italic>\u2009=\u2009.07). Among <jats:italic>APOE*E4<\/jats:italic> carriers, the annual DTI-FA decline was significantly lower in the group treated with \u03c9-3 than the placebo group (\u22120.0016 mm<jats:sup>2<\/jats:sup>\/s [95% CI, \u22120.0032 to 0.0020 mm<jats:sup>2<\/jats:sup>\/s] vs \u22120.0047 mm<jats:sup>2<\/jats:sup>\/s [95% CI, \u22120.0067 to \u22120.0025 mm<jats:sup>2<\/jats:sup>\/s]; <jats:italic>P<\/jats:italic>\u2009=\u2009.04). Adverse events were similar between treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this 3-year randomized clinical trial, \u03c9-3 treatment was safe and well-tolerated but failed to reach significant reductions in WML accumulation or neuronal integrity breakdown among all participants, which may be attributable to sample size limitations. However, neuronal integrity breakdown was reduced by \u03c9-3 treatment in <jats:italic>APOE*E4<\/jats:italic> carriers, suggesting that this treatment may be beneficial for this specific group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT01953705\">NCT01953705<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.26872","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T15:53:17Z","timestamp":1722527597000},"page":"e2426872","source":"Crossref","is-referenced-by-count":28,"title":["\u03c9-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults"],"prefix":"10.1001","volume":"7","author":[{"given":"Lynne H.","family":"Shinto","sequence":"first","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Murchison","sequence":"additional","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"},{"name":"Department of Biostatistics, University of Alabama, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Silbert","sequence":"additional","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"},{"name":"Portland VA, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko H.","family":"Dodge","sequence":"additional","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"},{"name":"Interdisciplinary Brain Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lahna","sequence":"additional","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rooney","sequence":"additional","affiliation":[{"name":"Advanced Imaging Research Center, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kaye","sequence":"additional","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"},{"name":"Portland VA, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Quinn","sequence":"additional","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"},{"name":"Portland VA, Portland, Oregon"},{"name":"Parkinson\u2019s Disease Center, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene L.","family":"Bowman","sequence":"additional","affiliation":[{"name":"NIA-Layton Aging and Alzheimer\u2019s Disease Center, Department of Neurology, Oregon Health & Science University, Portland"},{"name":"McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"9","key":"zoi240835r1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"issue":"19","key":"zoi240835r2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1212\/WNL.0b013e318236ef23","article-title":"Vascular risk factors and cognitive impairment in a stroke-free cohort.","volume":"77","author":"Unverzagt","year":"2011","journal-title":"Neurology"},{"issue":"12","key":"zoi240835r3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/jnen\/62.12.1287","article-title":"Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis\/lipohyalinosis with cognitive decline.","volume":"62","author":"Thal","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"zoi240835r4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1212\/WNL.0b013e3181ad53fd","article-title":"Cognitive impairment risk: white matter hyperintensity progression matters.","volume":"73","author":"Silbert","year":"2009","journal-title":"Neurology"},{"issue":"23","key":"zoi240835r5","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1212\/WNL.0000000000000505","article-title":"Presence and progression of white matter hyperintensities and cognition: a meta-analysis.","volume":"82","author":"Kloppenborg","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"zoi240835r6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12916-014-0206-2","article-title":"The overlap between vascular disease and Alzheimer\u2019s disease: lessons from pathology.","volume":"12","author":"Attems","year":"2014","journal-title":"BMC Med"},{"issue":"2","key":"zoi240835r7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3233\/JAD-170573","article-title":"White matter hyperintensities and cognition in mild cognitive impairment and Alzheimer\u2019s disease: a domain-specific meta-analysis.","volume":"63","author":"van den Berg","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"zoi240835r8","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1161\/STROKEAHA.117.018101","article-title":"Neuropathology of white matter lesions, blood-brain barrier dysfunction, and dementia.","volume":"48","author":"Hainsworth","year":"2017","journal-title":"Stroke"},{"issue":"11","key":"zoi240835r9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1212\/01.wnl.0000319691.50117.54","article-title":"Neuropathologic correlates of white matter hyperintensities.","volume":"71","author":"Young","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"zoi240835r10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1161\/01.STR.0000221308.94473.14","article-title":"White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury.","volume":"37","author":"Fernando","year":"2006","journal-title":"Stroke"},{"issue":"8","key":"zoi240835r11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1042\/CS20160380","article-title":"Pathogenesis of white matter changes in cerebral small vessel diseases: beyond vessel-intrinsic mechanisms.","volume":"131","author":"Joutel","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"zoi240835r12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.dadm.2016.12.011","article-title":"Peripheral inflammatory markers indicate microstructural damage within periventricular white matter hyperintensities in Alzheimer\u2019s disease: a preliminary report.","volume":"7","author":"Swardfager","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"zoi240835r13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.trci.2019.02.001","article-title":"White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities.","volume":"5","author":"Alber","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi240835r14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/1745509X.4.1.47","article-title":"Alzheimer\u2019s disease and the blood-brain barrier: past, present and future.","volume":"4","author":"Bowman","year":"2008","journal-title":"Aging health"},{"issue":"2","key":"zoi240835r15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1212\/01.wnl.0000194256.15247.83","article-title":"White matter damage on diffusion tensor imaging correlates with age-related cognitive decline.","volume":"66","author":"Charlton","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"zoi240835r16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.nurt.2007.05.011","article-title":"Diffusion tensor imaging of the brain.","volume":"4","author":"Alexander","year":"2007","journal-title":"Neurotherapeutics"},{"key":"zoi240835r17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neuroscience.2017.05.048","article-title":"Disrupted white matter structural networks in healthy older adult APOE e4 carriers: an international multicenter DTI study.","volume":"357","author":"Cavedo","year":"2017","journal-title":"Neuroscience"},{"issue":"6","key":"zoi240835r18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1212\/01.wnl.0000324414.12665.b0","article-title":"Fish consumption and risk of subclinical brain abnormalities on MRI in older adults.","volume":"71","author":"Virtanen","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"zoi240835r19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1212\/WNL.0b013e3182436598","article-title":"Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging.","volume":"78","author":"Bowman","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"zoi240835r20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000305","article-title":"Circulating omega-3 polyunsaturated fatty acids and subclinical brain abnormalities on MRI in older adults: the Cardiovascular Health Study.","volume":"2","author":"Virtanen","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"zoi240835r21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mam.2018.09.003","article-title":"Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection.","volume":"64","author":"Bazan","year":"2018","journal-title":"Mol Aspects Med"},{"issue":"4","key":"zoi240835r22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3945\/ajcn.111.025924","article-title":"Effects of n-3 PUFA supplementation on plasma soluble adhesion molecules: a meta-analysis of randomized controlled trials.","volume":"95","author":"Yang","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"zoi240835r23","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00394-017-1462-7","article-title":"Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1\u00df administration.","volume":"57","author":"Dong","year":"2018","journal-title":"Eur J Nutr"},{"issue":"12","key":"zoi240835r24","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jalz.2018.06.2857","article-title":"Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults.","volume":"14","author":"Bowman","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi240835r25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1093\/cercor\/bht163","article-title":"Long-chain omega-3 fatty acids improve brain function and structure in older adults.","volume":"24","author":"Witte","year":"2014","journal-title":"Cereb Cortex"},{"issue":"1","key":"zoi240835r26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.14283\/jpad.2017.23","article-title":"Effects of omega-3 fatty acids on resting cerebral perfusion in patients with mild cognitive impairment: a randomized controlled trial.","volume":"5","author":"Schwarz","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"key":"zoi240835r27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnagi.2013.00092","article-title":"Plasma omega-3 PUFA and white matter mediated executive decline in older adults.","volume":"5","author":"Bowman","year":"2013","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"zoi240835r28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/nu11040735","article-title":"Randomized trial of marine n-3 polyunsaturated fatty acids for the prevention of cerebral small vessel disease and inflammation in aging (PUFA Trial): rationale, design and baseline results.","volume":"11","author":"Bowman","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"zoi240835r29","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2307\/2533283","article-title":"Adaptive biased urn randomization in small strata when blinding is impossible.","volume":"51","author":"Schouten","year":"1995","journal-title":"Biometrics"},{"issue":"17","key":"zoi240835r30","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"issue":"9","key":"zoi240835r31","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.neurobiolaging.2007.03.004","article-title":"Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.","volume":"29","author":"Jack","year":"2008","journal-title":"Neurobiol Aging"},{"key":"zoi240835r32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.nicl.2015.04.012","article-title":"Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures.","volume":"8","author":"Promjunyakul","year":"2015","journal-title":"Neuroimage Clin"},{"issue":"4","key":"zoi240835r33","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.neuroimage.2006.02.024","article-title":"Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data.","volume":"31","author":"Smith","year":"2006","journal-title":"Neuroimage"},{"issue":"8","key":"zoi240835r34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1139\/o59-099","article-title":"A rapid method of total lipid extraction and purification.","volume":"37","author":"Bligh","year":"1959","journal-title":"Can J Biochem Physiol"},{"issue":"1","key":"zoi240835r35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1179\/1476830512Y.0000000025","article-title":"Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. servicemembers.","volume":"16","author":"Johnston","year":"2013","journal-title":"Nutr Neurosci"},{"issue":"1","key":"zoi240835r36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/2160763X11431107","article-title":"Relative bioavailability of an emulsion formulation for omega-3-acid ethyl esters compared to the commercially available formulation: a randomized, parallel-group, single-dose study followed by repeat dosing in healthy volunteers.","volume":"1","author":"Hussey","year":"2012","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"zoi240835r38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"issue":"11","key":"zoi240835r41","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1001\/archneurol.2010.284","article-title":"Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.","volume":"67","author":"Carmichael","year":"2010","journal-title":"Arch Neurol"},{"issue":"6","key":"zoi240835r42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jama.2019.10551","article-title":"Association of intensive vs standard blood pressure control with cerebral white matter lesions.","volume":"322","author":"Nasrallah","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"zoi240835r43","first-page":"948","article-title":"A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype.","volume":"60","author":"Payami","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"11","key":"zoi240835r44","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1212\/WNL.0000000000001379","article-title":"Effects of vascular risk factors and APOE e4 on white matter integrity and cognitive decline.","volume":"84","author":"Wang","year":"2015","journal-title":"Neurology"},{"key":"zoi240835r45","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.neuroimage.2018.12.009","article-title":"Vascular burden and APOE e4 are associated with white matter microstructural decline in cognitively normal older adults.","volume":"188","author":"Williams","year":"2019","journal-title":"Neuroimage"},{"issue":"11","key":"zoi240835r46","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","article-title":"APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGF\u00df-mediated checkpoints.","volume":"24","author":"Yin","year":"2023","journal-title":"Nat Immunol"},{"issue":"3","key":"zoi240835r47","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-191017","article-title":"Effect of APOE genotype on plasma docosahexaenoic acid (DHA), eicosapentaenoic acid, arachidonic acid, and hippocampal volume in the Alzheimer\u2019s Disease Cooperative Study-Sponsored DHA Clinical Trial.","volume":"74","author":"Tomaszewski","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"zoi240835r48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/joim.2014.275.issue-4","article-title":"Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer\u2019s disease: the OmegAD study.","volume":"275","author":"Freund Levi","year":"2014","journal-title":"J Intern Med"},{"issue":"12","key":"zoi240835r49","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1161\/ATVBAHA.108.171736","article-title":"In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid.","volume":"28","author":"Yamada","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"zoi240835r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105154","article-title":"Murine and human microglial cells are relatively enriched with eicosapentaenoic acid compared to the whole brain.","volume":"150","author":"Cisbani","year":"2021","journal-title":"Neurochem Int"},{"issue":"9","key":"zoi240835r51","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41593-023-01415-3","article-title":"Infiltrating CD8+ T cells exacerbate Alzheimer\u2019s disease pathology in a 3D human neuroimmune axis model.","volume":"26","author":"Jorfi","year":"2023","journal-title":"Nat Neurosci"},{"issue":"5","key":"zoi240835r52","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","article-title":"Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.","volume":"16","author":"Andrieu","year":"2017","journal-title":"Lancet Neurol"},{"issue":"13","key":"zoi240835r53","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jama.2011.383","article-title":"A potential design flaw of randomized trials of vitamin supplements.","volume":"305","author":"Morris","year":"2011","journal-title":"JAMA"},{"key":"zoi240835r54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-016-0201-2","article-title":"Older patients are still under-represented in clinical trials of Alzheimer\u2019s disease.","volume":"8","author":"Banzi","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"zoi240835r55","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2018.09.009","article-title":"Perspectives on ethnic and racial disparities in Alzheimer\u2019s disease and related dementias: update and areas of immediate need.","volume":"15","author":"Babulal","year":"2019","journal-title":"Alzheimers Dement"},{"key":"zoi240835r39","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-0318-1","volume-title":"Mixed-Effects Models in S and S-PLUS","author":"Pinheiro","year":"2000"},{"key":"zoi240835r40","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"zoi240835r37","unstructured":"R Foundation for Statistical Computing. R: a language and environment for statistical computing. Accessed June 27, 2024. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2821809\/shinto_2024_oi_240835_1721852037.57734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T15:53:22Z","timestamp":1722527602000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2821809"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.26872","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}